Stockscreener 앱 받기
16.12
1.83%
0.29
시간 외 거래:
16.19
0.07
+0.43%
Liquidia Corp 주식(LQDA)의 최신 뉴스
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month - Seeking Alpha
UTC can't counterclaim over amended Liquidia drug application, US judge says - MLex
Liquidia (LQDA) Receives Price Target Upgrade from Scotiabank | LQDA Stock News - GuruFocus
Liquidia (LQDA): Scotiabank Raises Price Target and Maintains Outperform Rating | LQDA Stock News - GuruFocus
Scotiabank raises Liquidia stock price target to $36 By Investing.com - Investing.com India
Scotiabank raises Liquidia stock price target to $36 - Investing.com
Legal Victory for Liquidia Corporation (LQDA) in YUTREPIA Inhalation Powder Case | LQDA Stock News - GuruFocus
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - The Manila Times
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.
Liquidia Technologies stock surges on legal win By Investing.com - Investing.com South Africa
Liquidia Technologies stock surges on legal win - Investing.com Australia
Liquidia (LQDA) Clears Legal Hurdle, Prepares for Yutrepia Launch | LQDA Stock News - GuruFocus
Liquidia (LQDA) Jumps 15% as Court Clears Path for Yutrepia Launch - GuruFocus
Liquidia (LQDA) Price Target Increased Following Legal Victory | LQDA Stock News - GuruFocus
UTC Bid to Delay Liquidia’s Yutrepia Launch Shot Down by Judge - Bloomberg Law News
Liquidia surges 15% as court clears way for Yutrepia launch (updated) - Seeking Alpha
Deeper Dive: Understanding Liquidia Corp (LQDA) Through its Various Ratios - DWinneX
Did Liquidia Corp (LQDA) perform well in the last session? - uspostnews.com
Does Liquidia Corp (LQDA) offer a good opportunity for investors? - Sete News
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
LQDA: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Liquidia Corp [LQDA] Stock sold by Insider Saggar Rajeev for $33492.0 - knoxdaily.com
Liquidia Corp's chief medical officer sells $31,785 in stock - MSN
Was anything positive for Liquidia Corp (LQDA) stock last session? - uspostnews.com
Liquidia Corp files patent infringement suit against United Therapeutics By Investing.com - Investing.com Canada
Liquidia Corp files patent infringement suit against United Therapeutics - Investing.com
Liquidia Sues UTC Seeking Patent Damages for Tyvaso DPI Drug (1) - Bloomberg Law News
Liquidia Corp’s chief medical officer sells $50,398 in stock By Investing.com - Investing.com Canada
Liquidia Corp Executives Sell Shares Under Rule 10b5-1 Plan - TradingView
Liquidia Corp’s chief medical officer sells $50,398 in stock - Investing.com
Liquidia Corp’s chief business officer Jason Adair sells shares worth $25,185 - Investing.com India
Great week for Liquidia Corporation (NASDAQ:LQDA) institutional investors after losing 1.5% over the previous year - Yahoo Finance
Breaking Down Liquidia: 4 Analysts Share Their Views - Benzinga
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch - Investing.com Australia
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch By Investing.com - Investing.com India
Liquidia: United Therapeutics Has The Last Laugh (LQDA) - Seeking Alpha
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Liquidia (NASDAQ:LQDA) - Defense World
Liquidia Corp (LQDA) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
UPDATELiquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Liquidia Technologies (LQDA) Receives a Buy from Scotiabank - The Globe and Mail
Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Average Price Target from Analysts - The AM Reporter
Liquidia says its request for Yutrepia final approval undergoes FDA review - MSN
Liquidia stock rises as Yutrepia undergoes FDA review (LQDA) - Seeking Alpha
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder - Investing.com
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA - TipRanks
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder By Investing.com - Investing.com Canada
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - The Manila Times
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
What is Lifesci Capital’s Estimate for Liquidia Q2 Earnings? - The AM Reporter
Liquidia Corporation (NASDAQ:LQDA) Q4 2024 Earnings Call Transcript - Insider Monkey
0.39%
3.66%
자본화:
|
볼륨(24시간):